Learn about how POTELIGEO works, POTELLIGENT® technology, the role of C-C chemokine receptor type 4 (CCR4),1 and key points of the infusion process.
Explore POTELLIGENT technology, an innovative approach designed to enhance antibody-dependent cellular cytotoxicity.
POTELIGEO and the CCR4 target
Learn why CCR4 is a key target for mycosis fungoides and Sézary syndrome, and how POTELIGEO targets CCR4-positive T-cells.1
Kyowa Kirin Cares connects the dots
See how Kyowa Kirin Cares is dedicated to helping patients throughout their journey with a variety of helpful support resources.
POTELIGEO® Points virtual library
Take a virtual tour of all things POTELIGEO with these short, information-packed vignettes.
The MAVORIC trial patient population
Explore the diverse patient population and key efficacy results of POTELIGEO vs vorinostat.1
POTELIGEO efficacy in skin
Learn about the response of POTELIGEO in skin, based on a post-hoc analysis of data in the MAVORIC clinical trial.1
How POTELIGEO uniquely targets CCR4
Learn about the role of C-C chemokine receptor type 4 (CCR4) in mycosis fungoides (MF) and Sézary syndrome (SS), and how POTELIGEO kills CCR4+ malignant T-cells.1
Be sure to sign up so we can keep you informed of updates
and new materials in the POTELIGEO Digital Library.
- POTELIGEO [package insert]. Kyowa Kirin Inc., Bedminster, NJ USA.